Lurasidone in the treatment of schizophrenia: a critical evaluation

Expert Opinion on Pharmacotherapy
Dawn BruijnzeelRajiv Tandon

Abstract

Antipsychotic medications are the foundation of the pharmacological treatment of schizophrenia and lurasidone is the most recent of the 65 agents around the world to become available. In order to use it optimally, it is important to understand its pharmacological and clinical nature and its comparative effectiveness to other antipsychotic agents in the treatment of schizophrenia. Following a comprehensive review of the literature, this article summarizes current information about the pharmacology of lurasidone, data about its short- and long-term efficacy and safety/tolerability in the treatment of schizophrenia, its comparative effectiveness to other antipsychotic agents, and guidance about its optimal use in the treatment of individuals with schizophrenia. Lurasidone is a benzoisothiazole with potent dopamine D2 and serotonin 5HT2A antagonist and serotonin 5HT1A partial agonist properties (like other second-generation antipsychotic agents) with additional potent 5HT7 and alpha2C noradrenergic antagonism. It has little or no activity at the alpha1 and alpha2A noradrenergic, 5HT2C serotonergic, histaminergic and cholinergic receptors. Available only in an oral formulation, it is effective in once-daily dosing (40 - 160 mg/day) ...Continue Reading

References

Jul 8, 2017·Expert Opinion on Investigational Drugs·Lynn McClellanCraig A Erickson
Jul 19, 2017·Expert Opinion on Drug Discovery·Awais Aftab, Keming Gao
Mar 4, 2020·CNS & Neurological Disorders Drug Targets·Harika Modugula, Anoop Kumar
Oct 22, 2020·Brain Sciences·Samskruthi Madireddy, Sahithi Madireddy

Citations

Jan 1, 1992·Psychopathology·R S GoldmanJ F Greden
Nov 1, 1991·Biological Psychiatry·S F TaylorA Eiser
Feb 1, 1996·Biological Psychiatry·S HimelhochRajiv Tandon
Jul 18, 2001·Comprehensive Psychiatry·A TappRajiv Tandon
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeNeurocognitive Working Group
Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraA Loebel
Sep 29, 2009·Expert Opinion on Investigational Drugs·Jonathan M MeyerEdward Schweizer
Jul 27, 2010·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan
Oct 7, 2010·The Journal of Clinical Psychiatry·John M Kane, Christoph U Correll
Jan 11, 2012·The Journal of Clinical Psychiatry·Rajiv Tandon
Mar 8, 2012·International Clinical Psychopharmacology·Leslie CitromeA Loebel
Apr 17, 2012·Schizophrenia Bulletin·Rajiv Tandon, William Carpenter
Aug 21, 2012·Psychopharmacology·Masaaki OgasaJohn Guarino
Dec 25, 2012·CNS Drugs·Mark Sanford
May 7, 2013·Asian Journal of Psychiatry·William Carpenter, Rajiv Tandon
May 28, 2013·Schizophrenia Research·Stephan HeckersWilliam Carpenter
Jun 19, 2013·Schizophrenia Research·Ming T TsuangWilliam Carpenter
Jun 27, 2013·Schizophrenia Research·Rajiv TandonWilliam Carpenter
Sep 17, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Philip D HarveyA Loebel
Jan 31, 2014·Neuropsychiatric Disease and Treatment·Francisco Torres-GonzálezManuel Gómez-Beneyto
Mar 4, 2014·The Journal of Clinical Psychiatry·Leslie Citrome
May 16, 2014·Drug Metabolism and Drug Interactions·Yu-Yuan ChiuA Loebel
Oct 5, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·A LoebelS R Marder

Related Concepts

Metabolic Process, Cellular
PRL
Schizophrenia
Serotonin Measurement
Food
Serotonin
Occlusal Guidance
Antagonist Muscle Action
Molecular_function
2-phenyl-1,2-benzisothiazol-3-(2H)-one

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

International Journal of Clinical Practice
D M Taylor
Neuropsychiatric Disease and Treatment
Silvio CacciaAlessandro Nobili
Expert Opinion on Pharmacotherapy
Philip D Harvey, Christopher R Bowie
Therapeutics and Clinical Risk Management
Ludovic SamalinPierre-Michel Llorca
© 2020 Meta ULC. All rights reserved